Identifying biomarker-driven subphenotypes of cardiogenic shock: analysis of prospective cohorts and randomized controlled trials.

IF 9.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL EClinicalMedicine Pub Date : 2024-12-18 eCollection Date: 2025-01-01 DOI:10.1016/j.eclinm.2024.103013
Sabri Soussi, Tuukka Tarvasmäki, Antoine Kimmoun, Mojtaba Ahmadiankalati, Feriel Azibani, Claudia C Dos Santos, Kevin Duarte, Etienne Gayat, Jacob C Jentzer, Veli-Pekka Harjola, Benjamin Hibbert, Christian Jung, Lassus Johan, Bruno Levy, Zihang Lu, Patrick R Lawler, John C Marshall, Janine Pöss, Malha Sadoune, Alexis Nguyen, Alexandre Raynor, Katell Peoc'h, Holger Thiele, Rebecca Mathew, Alexandre Mebazaa
{"title":"Identifying biomarker-driven subphenotypes of cardiogenic shock: analysis of prospective cohorts and randomized controlled trials.","authors":"Sabri Soussi, Tuukka Tarvasmäki, Antoine Kimmoun, Mojtaba Ahmadiankalati, Feriel Azibani, Claudia C Dos Santos, Kevin Duarte, Etienne Gayat, Jacob C Jentzer, Veli-Pekka Harjola, Benjamin Hibbert, Christian Jung, Lassus Johan, Bruno Levy, Zihang Lu, Patrick R Lawler, John C Marshall, Janine Pöss, Malha Sadoune, Alexis Nguyen, Alexandre Raynor, Katell Peoc'h, Holger Thiele, Rebecca Mathew, Alexandre Mebazaa","doi":"10.1016/j.eclinm.2024.103013","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiogenic shock (CS) is a heterogeneous clinical syndrome, making it challenging to predict patient trajectory and response to treatment. This study aims to identify biological/molecular CS subphenotypes, evaluate their association with outcome, and explore their impact on heterogeneity of treatment effect (ShockCO-OP, NCT06376318).</p><p><strong>Methods: </strong>We used unsupervised clustering to integrate plasma biomarker data from two prospective cohorts of CS patients: CardShock (N = 205 [2010-2012, NCT01374867]) and the French and European Outcome reGistry in Intensive Care Units (FROG-ICU) (N = 228 [2011-2013, NCT01367093]) to determine the optimal number of classes. Thereafter, a simplified classifier (Euclidean distances) was used to assign the identified CS subphenotypes in three completed randomized controlled trials (RCTs) (OptimaCC, N = 57 [2011-2016, NCT01367743]; DOREMI, N = 192 [2017-2020, NCT03207165]; and CULPRIT-SHOCK, N = 434 [2013-2017, NCT01927549]) and explore heterogeneity of treatment effect with respect to 28-day mortality (primary outcome).</p><p><strong>Findings: </strong>Four biomarker-driven CS subphenotypes ('adaptive', 'non-inflammatory', 'cardiopathic', and 'inflammatory') were identified separately in the two cohorts. Patients in the inflammatory and cardiopathic subphenotypes had the highest 28-day mortality (p (log-rank test) = 0.0099 and 0.0055 in the CardShock and FROG-ICU cohorts, respectively). Subphenotype membership significantly improved risk stratification when added to traditional risk factors including the Society for Cardiovascular Angiography and Interventions (SCAI) shock stages (increase in Harrell's C-index by 4% (<i>p</i> = 0.033) and 6% (<i>p</i> = 0.0068) respectively in the CardShock and the FROG-ICU cohorts). The simplified classifier identified CS subphenotypes with similar biological/molecular and outcome characteristics in the three independent RCTs. No significant interaction was observed between treatment effect and subphenotypes.</p><p><strong>Interpretation: </strong>Subphenotypes with the highest concentration of biomarkers of endothelial dysfunction and inflammation (inflammatory) or myocardial injury/fibrosis (cardiopathic) were associated with mortality independently from the SCAI shock stages.</p><p><strong>Funding: </strong>Dr Sabri Soussi was awarded the Canadian Institutes of Health Research (CIHR) Doctoral Foreign Study Award (DFSA) and the Merit Awards Program (Department of Anesthesiology and Pain Medicine, University of Toronto, Canada) for the current study.</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":"79 ","pages":"103013"},"PeriodicalIF":9.6000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718329/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2024.103013","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cardiogenic shock (CS) is a heterogeneous clinical syndrome, making it challenging to predict patient trajectory and response to treatment. This study aims to identify biological/molecular CS subphenotypes, evaluate their association with outcome, and explore their impact on heterogeneity of treatment effect (ShockCO-OP, NCT06376318).

Methods: We used unsupervised clustering to integrate plasma biomarker data from two prospective cohorts of CS patients: CardShock (N = 205 [2010-2012, NCT01374867]) and the French and European Outcome reGistry in Intensive Care Units (FROG-ICU) (N = 228 [2011-2013, NCT01367093]) to determine the optimal number of classes. Thereafter, a simplified classifier (Euclidean distances) was used to assign the identified CS subphenotypes in three completed randomized controlled trials (RCTs) (OptimaCC, N = 57 [2011-2016, NCT01367743]; DOREMI, N = 192 [2017-2020, NCT03207165]; and CULPRIT-SHOCK, N = 434 [2013-2017, NCT01927549]) and explore heterogeneity of treatment effect with respect to 28-day mortality (primary outcome).

Findings: Four biomarker-driven CS subphenotypes ('adaptive', 'non-inflammatory', 'cardiopathic', and 'inflammatory') were identified separately in the two cohorts. Patients in the inflammatory and cardiopathic subphenotypes had the highest 28-day mortality (p (log-rank test) = 0.0099 and 0.0055 in the CardShock and FROG-ICU cohorts, respectively). Subphenotype membership significantly improved risk stratification when added to traditional risk factors including the Society for Cardiovascular Angiography and Interventions (SCAI) shock stages (increase in Harrell's C-index by 4% (p = 0.033) and 6% (p = 0.0068) respectively in the CardShock and the FROG-ICU cohorts). The simplified classifier identified CS subphenotypes with similar biological/molecular and outcome characteristics in the three independent RCTs. No significant interaction was observed between treatment effect and subphenotypes.

Interpretation: Subphenotypes with the highest concentration of biomarkers of endothelial dysfunction and inflammation (inflammatory) or myocardial injury/fibrosis (cardiopathic) were associated with mortality independently from the SCAI shock stages.

Funding: Dr Sabri Soussi was awarded the Canadian Institutes of Health Research (CIHR) Doctoral Foreign Study Award (DFSA) and the Merit Awards Program (Department of Anesthesiology and Pain Medicine, University of Toronto, Canada) for the current study.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
识别生物标志物驱动的心源性休克亚表型:前瞻性队列和随机对照试验的分析。
背景:心源性休克(CS)是一种异质性的临床综合征,因此很难预测患者的治疗轨迹和对治疗的反应。本研究旨在鉴定生物学/分子CS亚表型,评估其与预后的相关性,并探讨其对治疗效果异质性的影响(ShockCO-OP, NCT06376318)。方法:我们采用无监督聚类方法整合来自两个前瞻性CS患者队列的血浆生物标志物数据:CardShock (N = 205 [2010-2012, NCT01374867])和法国和欧洲重症监护病房(FROG-ICU)结局登记(N = 228 [2011-2013, NCT01367093]),以确定最佳分类数量。随后,在三个已完成的随机对照试验(RCTs)中,使用简化分类器(欧氏距离)对鉴定出的CS亚表型进行分配(OptimaCC, N = 57 [2011-2016, NCT01367743];Doremi, n = 192 [2017-2020, nct03207165];和元凶-休克,N = 434 [2013-2017, NCT01927549]),并探讨治疗效果在28天死亡率(主要结局)方面的异质性。研究结果:在两个队列中分别确定了四种生物标志物驱动的CS亚表型(“适应性”、“非炎症”、“心脏病”和“炎症”)。炎症亚表型和心脏病亚表型的患者28天死亡率最高(CardShock和FROG-ICU队列的p (log-rank检验)分别= 0.0099和0.0055)。当加入包括心血管血管造影和干预学会(SCAI)休克阶段在内的传统危险因素时,亚表型隶属度显著改善了风险分层(CardShock组和FROG-ICU组的Harrell C-index分别增加了4% (p = 0.033)和6% (p = 0.0068))。简化分类器在三个独立的随机对照试验中识别出具有相似生物学/分子和结局特征的CS亚表型。在治疗效果和亚表型之间没有观察到显著的相互作用。解释:内皮功能障碍和炎症(炎症性)或心肌损伤/纤维化(心脏病性)生物标志物浓度最高的亚表型与SCAI休克阶段独立的死亡率相关。资助:Sabri Soussi博士因目前的研究获得了加拿大卫生研究院(CIHR)博士国外学习奖(DFSA)和优秀奖计划(加拿大多伦多大学麻醉学和疼痛医学系)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
EClinicalMedicine
EClinicalMedicine Medicine-Medicine (all)
CiteScore
18.90
自引率
1.30%
发文量
506
审稿时长
22 days
期刊介绍: eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
期刊最新文献
Global, regional, national burden of asthma from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021. Alcohol use and HIV suppression after completion of financial incentives for alcohol abstinence and isoniazid adherence: a randomized controlled trial. Expression of concern-Effectiveness of strategies for implementing guideline-concordant care in low back pain: a systematic review and meta-analysis of randomised controlled trials. O' testosterone, where is thy sting? A Urologist's reflection on testosterone and prostate cancer. Preoperative and intraoperative neuromonitoring and mapping techniques impact oncological and functional outcomes in supratentorial function-eloquent brain tumours: a systematic review and meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1